الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 108 |  |  |
| | | from | 108 | | |
Abstract
A cataract is the leading cause of reversible blindness throughout the world. Cataract surgery is one of the most commonly performed surgeries worldwide.
Anterior segment inflammation is one of the most commonly occurring complications following phacoemulsification. It is due to surgical trauma in cataract surgery and the later chronic immune reaction of the uvea to the implanted foreign body, the intraocular lens (IOL).
Pseudo-phakic cystoid macular edema (PCME) remains one of the most frequent postoperative complications leading to unfavorable visual outcomes. The pathogenesis of PCME is multifactorial but remains unclear; the current leading theory suggests a significant role in inflammatory processes and increased levels of intraocular prostaglandins and other inflammatory mediators released during surgical trauma.
Topical steroids are commonly used for 2 to 6 weeks post-operation to control inflammation; they are the most prescribed medication for postoperative inflammation. Prednisolone is one of the most widely used corticosteroids. Although topical ocular corticosteroids are vital to treating postoperative inflammation, their prolonged use can produce side effects, such as elevated intraocular pressure (IOP), lowered resistance to infection, and may interfere with wound healing.
Ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs) eye drops offer equivalent anti-inflammatory efficacy to corticosteroids in uneventful cataract surgery but without the side effects of corticosteroids. Following topical ocular administration, Nepafenac has demonstrated superior intraocular penetration compared to other anti-inflammatory drugs in both anterior segment and retinal tissue.